|
Mar 28
|
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
|
|
Mar 8
|
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
|
|
Feb 15
|
Organon Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 13
|
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
|